AKT1 and cancer: As our series included many cases of metastatic breast cancer, we also carried out exploratory analysis of the association between PIK3CA mutations and response to different types of anti-cancer treatments, such as chemotherapy and pharmacological agents targeting the PI3K-AKT-mTOR pathway.